Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
Andrea B. Apolo(National Institutes of Health), Jonathan E. Rosenberg(Memorial Sloan Kettering Cancer Center), Colleen Watt(National Cancer Institute), Alan W.C. Tan(National Cancer Institute), Elad Sharon(National Cancer Institute), Min Yuen Teo(National Cancer Institute), Petros Grivas(Fred Hutch Cancer Center), Jiaoti Huang(Duke University), Rahul Atul Parikh(National Cancer Institute), Meagan Odegaard(National Cancer Institute), Daniel M. Geynisman(Fox Chase Cancer Center), Nicholas I. Simon(National Cancer Institute), Cecilia Mitchell(National Cancer Institute), Lisa M. Cordes(National Institutes of Health Clinical Center), Scot A. Niglio(National Cancer Institute), Mehmet Asım Bilen(Emory University), Daniel P. Petrylak(Radboud University Nijmegen), Guru Sonpavde(Dana-Farber Cancer Institute), Susan Halabi(Duke University), Yujia Wen(National Cancer Institute), Bradley A. McGregor(Harvard University), Joseph W. Kim(National Cancer Institute), Michael Woods(National Cancer Institute), Stephanie Berg(Loyola University Medical Center), Randy F. Sweis(National Cancer Institute), Karla V. Ballman(National Cancer Institute), Parminder Singh(Buck Institute for Research on Aging), Suzanne Cole(National Cancer Institute), Abhishek Tripathi(Dana-Farber Cancer Institute), Jeannie Hoffman-Censits(National Cancer Institute), William Y. Kim(University of North Carolina at Chapel Hill), Gurkamal Chatta(Roswell Park Comprehensive Cancer Center), Howard Streicher(National Cancer Institute), Zachery R. Reichert(National Cancer Institute), Lisa Ley(National Cancer Institute), Sandy Srinivas(Stanford University), Helen Moon(National Cancer Institute), Michael J. Morris(The University of Texas Southwestern Medical Center), Olwen Hahn(National Cancer Institute), Gabriela Perez Burbano(National Cancer Institute)
Cited by 145
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k